Anti-α4β7 Antibody Formulation for Stability and Aggregate Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations for anti-α4β7 antibodies are unstable, prone to degradation pathways such as deamidation, oxidation, and aggregation, which affects their efficacy and stability, and there is a need for suitable dosages and dosing schedules to treat inflammatory bowel diseases effectively.
Innovation Solution
A formulation comprising a non-reducing sugar and at least one free amino acid, with specific molar ratios, along with optional surfactants and buffering agents, stabilizes the anti-α4β7 antibody, minimizing degradation and maintaining therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If anti-α4β7 antibody is formulated without specific stabilizing excipients, then the formulation process is simple, but the antibody is unstable and prone to degradation
Solution Approach 1:
The patent introduces specific excipients (surfactants, buffering agents, and non-reducing sugars) as intermediary substances that mediate between the antibody and degradation pathways. These excipients act as protective intermediaries that prevent direct contact between the antibody and harmful environmental factors, thereby stabilizing the antibody without fundamentally changing its structure.
Solution Approach 2:
The patent modifies formulation parameters by specifying precise concentrations and ratios of stabilizing excipients. By optimizing parameters such as surfactant concentration (0.001-1.0%), buffering agent levels (50-500 mM), and sugar-to-antibody ratios (>600:1), the formulation achieves enhanced stability while maintaining manageable complexity through defined parameter ranges.
2Duration of action of stationary object
If the formulation extends shelf life to at least three months at 40°C and 75% RH, then storage stability is improved, but the formulation complexity increases
Solution Approach 1:
The patent incorporates stabilizing excipients into the formulation before storage to prevent degradation pathways from occurring in the first place. The surfactants, buffering agents, and non-reducing sugars are pre-added at optimized concentrations to create a protective environment that prevents protein degradation, aggregation, and immunogenicity during extended storage at elevated temperatures and humidity.
Solution Approach 2:
The patent creates a composite formulation system combining the anti-α4β7 antibody with multiple stabilizing excipients (surfactants, buffering agents, and non-reducing sugars). This composite approach leverages the synergistic effects of different excipients to achieve extended shelf life, where each component contributes specific protective functions that collectively enable stable storage for at least three months under challenging conditions.
3Reliability
If the formulation reduces aggregate formation and immunogenicity, then the safety and efficacy are improved, but the formulation development complexity increases
Solution Approach 1:
The patent employs surfactants and buffering agents as intermediary substances that mediate between the antibody and aggregation pathways. These excipients create a protective interface that prevents direct protein-protein interactions leading to aggregates, and simultaneously reduces immunogenic responses, thereby enhancing therapeutic reliability without requiring overly complex formulation strategies.
4Stability of the object's composition
If specific molar ratios of non-reducing sugar to antibody are used (>600:1), then stability is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent establishes a minimum threshold for the non-reducing sugar-to-antibody molar ratio (>600:1) rather than requiring an exact target value. This parameter-based approach provides sufficient stability enhancement while allowing manufacturing flexibility, as long as the ratio exceeds the threshold, thereby reducing the stringency of precision requirements compared to exact ratio specifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation enhances the stability and reduces aggregate formation of anti-α4β7 antibodies, allowing for extended therapeutic efficacy with reduced immunogenicity and improved treatment outcomes for inflammatory bowel diseases.
Implementation Method 1
A formulation comprising a non-reducing sugar and at least one free amino acid in specific molar ratios, along with optional surfactants and buffering agents, stabilizes anti-α4β7 antibodies, minimizing degradation and immunogenicity
Implementation Method 2
The formulation maintains the stability and biological activity of anti-α4β7 antibodies, reducing aggregate formation and extending shelf life
Data Source
AI summary
Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.